CDKN2A and head and neck squamous cell carcinoma: CDK4/6 inhibitors hold promise in HNSCC where CDKN2A/p16 deletion and/or amplification of CCND1 (encoding Cyclin D1) frequently occur, ultimately causing sustained CDK4/6 activation.